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Abstract Etoposide is becoming important in primary and salvage therapy for 
ovarian cancer. In the present study， we administered etoposide 000-300 mg/subject) 
intraperitoneally to six patients suffering from cancerous peritonitis， particularly that 
resulting from ovarian cancer， to investigate the bioavailability and pharmacokinetics of 
this drug. The peak etoposide level in the ascites was 80μg/ml. Twelve hours after 
intrapertoneal administration (i. p.)， more than 10μg/ml of etoposide was stil found in 
ascites. The serum level after administration of 100 mg i.p. reached approximately 4μg/ 
ml within 30 minutes， and 1μg/ml of etoposide was stil found in serum after 24 hours. The 
etoposide levels in ascites and serum after 300 mg i.p. were higher than those after 100 mg 
i. p目 Whenthe peritoneum was intact， the area under the curve (AUC) of etoposide in 
ascites was low 064μg' h/ml) ， and the peritoneal clearance (Clp) was high. In contrast， 
in advanced cancerous peritonitis， the AUC in ascites was high (500μg • h./ml) and the Clp 
was low. The AUC of etoposide in the ascites of patients with cancerous peritonitis was 
more than five-fold greater than that of patients with an intact peritoneum， while MRT 
(mean residence time) was 15-fold， and VRT (variance of residence time) was 300-fold 
greater. The AUC ratio in intact peritoneum was 4.1， and that in cancerous peritonitis 
ranged from 17.8 to 27.1. AUC， MRT and VRT of etoposide transported into the blood 
were slightly higher in advanced cases than in those with intact peritoneum. These findings 
indicate that intraperitoneal etoposide han not only a direct anticancer effect in the 
abdominal cavity but also shows effects via the vascular system of the tumor. 
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Abbreviations 
AUC: area under the curve， Clp: peritoneal clearance， MRT: mean residence time， 
VRT : variance of residence time， Kel : the rate of disappearance from the abdominal 
cavity 
INTRODU CTION 
To increase the efficacy of anticancer agents， it is important to elevate the drug level at the 
site of tumor tissues. In particular， introducing anticancer agents directly into the peritoneal 
cavity of patients with cancerous peritonitis may expose individual free-floating tumor cells as 
well as small surface tumor nodules to much higher drug levels than those achieved with 
systemic infusions1，2l. However， many questions regarding optimal drugs and dosing schedules 
for intraperitoneal chemotherapy stil remain unanswered. 
We should be aware of the pharmacodynamics of intraperitoneally administrated drugs and 
have access to clinical pharmacological evaluations， since individual patients have different 
clinical conditions. 
Recently， etoposide， a semisynthetic podophyllotoxin derivative， has been gaining importance 
in both prima訂ryand salvage t出he臼rapyfor ovarian cancer3，4ベ
sal日lyfavorable results as a single agen此t，it appears to be useful when administered in combina-
tion with cisplatin or carboplatin5，6，7). 
In the present study， we administered etoposide intraperitoneally to patients with cancerous 
peritonitis， particularly that resulting from ovarian cancer. The bioavailability and phar戸
macodynamics of etoposide were assessed using a two-compartment model and moment 
analysis. An additional aim of this study was to determine whether concomitant treatment 
with cisplatin yielded favorable results in the treatment of cancerous peritonitis 
MATERIALS AND METHODS 
Patients 
Six adult female patients with cancerous peritonitis were studied ; their characteristics are 
shown in Table l. All cases had creatinine clearance (Ccr) greater than 80 ml/min.， white 
blood cell (WBC) count greater than 3.000/μ1 and platelet count greater than 10 X104 /μ1. 
Chemotherapy 
Patients were treated with a regimen of intraperitoneal administration with etoposide and 
cisplatinum on a monthly schedule. A maximum of three courses of therapy was delivered， 
followed by a response evaluation. The starting dose of etoposide was 100 mg/subject and that 
of cisplatinum was fixed at 50 mg/m2. In an individual patient， dose escalation of etoposide was 
permitted up to 300 mg/subject， ifdisease progression had been demonstrated after standard 
Pharmacokinetics of intraperitoneal巴toposid巴 (303) 
induction-treatment with a platimum-based combination chemotherapy. Both agents were 
administered intraperitoneally as rapidly as possible， and were diluted in 500 ml of physiological 
sa1ine when ascites was not found and without dilution when considerable ascites(> 500 ml)was 
found via exploratory laparotomy or abdominal punctation. 
Samples 
Blood samples were taken from a peripheral vein. Ascites samples were taken using an 
indwelling abdominal drain and were heparinized. Urine specimens were also collected and al 
samples were frozen at -200C until analysis. Samples were drawn before and at 0.25， 0.5， 1， 
2， 3， 4， 6， 12， 24 and 48 hours after administration. 
Etoposide assay 
The etoposide levels in these specimens were measured using high-performance 1iquid 
chromatography with a fluorescence detector8). These samples were added to 4' -demethyle-
pipodophyllotoxin 9-(4， 6-propylideneβD-glucopyranoside) as an internal standard. Extrac-
tion was performed with chloroform. The chloroform phase was dried in a vacuum， then 
redissolved with a 0.25 ml mobile phase [0.02 MKH2 P04 CH3 CN (57: 43， v /v) ] . This 
solution was injected onto a column (Senshu Pak ODS-2251-D) and analyzed with a detector 
(650-10 S， Hitachi Factory Co.， Ltd.， Tokyo， J apan) using an excitation wavelength of 290 nm 
and a fluorescence wavelength of 320 nm. The flow-rate retention time for this assay was 7.6 
min. and the lower 1imit of detection for etoposide in plasma was 5 ng/ml. 
Pharmacokinetic calculatio耳目
Etoposide concentration vs time was evaluated using a nonlinear leastsquares model analysis 
incorporating a two-compartment model and by moment analysis without a model 
RESULTS 
Time-course changes in etoposide levels in the ascites 
The time courses of changes in etoposide levels in the ascites and serum after intraperitoneal 
administration of 100 mg of etoposide in five cases are shown in Fig. 1. The mean levels and 
standard deviations are shown in Fig. 2. There were some individual variations ; however， 
relatively high levels in ascites were maintained for about 30 min. after administration， 
averaging 60 to 80μg/ml and reaching a maximum of 179μg/ml. 
These levels decreased slowly as more than 10μg/ml of etoposide was stil found in the 
ascites 12 hours after administration. However， in Case 1， the abdominal fluid diappeared 
Table 1. Characteristics of patients receiving i. p. etoposid巴
Dose of Ar巴aof body 
Patient Age Histology Stage Asci tes (mJ) etoposid巴 surfac巴
No. (mg/subject) (m') 
73 Mucinous* (uvary) 1 a No 10 1.36 
2 47 Serous Ca (uvary) IIc 150 10 1.5 
3 56 Mucinous Ca. (uvary) IIc No 10 1.4 
4 70 Serous Ca (uvary) IV 150 10 1.50 
5 61 Pancreas Ca IV 300 10 1. 48 
6 46 Mucinous Ca (uvary) IV 150 30D 1.52 
: borderline malignancy 
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Case 1 : 73 y.Q.， mucinous cystadenema (of borderline malignancy) Case 2 : 47 y.O.， serous cystadenocarcinoma 
stage 1 a， ascites (ー stage • c， ascites (+)， peritonitis carcinornatosa 
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Case 3 : 56 y.O.， mucinOU5 cystadenocarcinoma 
stage I c， ascites (+)， peritonites carcinomatosa 
Case 4 : 70 y.Q.， serOU5 cystadenocarcinoma 
stage N， ascites (+)， peritonitis carcionomalosa 
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Fig. 1. Cencentration curves of etoposide in ascites and plasma after intraperitoneal administration of 
巴toposide..一一・ Etoposid巴 inascites， 0--------0 : Etoposide in plasma 














Fig. 2. Concentration curv巴sfor etoposide in ascites 
and plasma after intraperitoneal administra-
tion of 10 mg etoposide. The data repr巴S巴nt
the mean:tS. D. for five patients. 
.--. : Etoposide in ascit巴s. 0 ← O 
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Fig. 3. Conc巴ntrationcurves of etoposide in ascites 
and plasma目・圃:Etoposide in ascites (30 mg i.p.)， - Etoposidein ascites (10 mg i.p.) 
口一司:Etoposide in plasma (30 mg i.p.)， 
0---0 : Etoposide in plasma (10 mg i.p.) 
x -X : Etoposid 巴 in plasma (80 mg/m2凶1子刊勺i.v 目〕
ム一一一一一-ム :E酌to叩pos剖id必ein plasma 060 mg/mヤ
Oω.) P町f巴ぱef任fた巴rM. et a剖1.1印987 
rapidly from the abdominal cavity ; thus， samples could be obtained only up to 90 min. 
Etoposide 300 mg i.p. was administered in Case 6. As shows in Fig. 3， the etoposide level in 
the ascites was notably higher than in the group treated with 100 mg of etoposide. The 
maximum level 1 hour after administration was 106μg/ml. More than 50μg/ml of etoposide 
was sti1 found in the ascites 24 hours after administration. 
Time-cour日echanges in etoposide levels in自erum
The transportation of etoposide into the bloodstream after intraperitoneal administration 
was relatively good (Figs. 1 and 2) ; inCases 1 and 2， etoposide reached a level of approximate 
ly 4μg/ml in serum at 30 to 40 min. after administration. This level decreased slowly ; 1μg/ 
ml of etoposide was sti1 found in the blood after 24 hours. However， in Case 4， a maximum 
of 4μg/ml of etoposide was maintained in the blood for nearly 12 hours， showing no elimination 
phase. In Case 5， the serum level of etoposide increased rather slowly up to 24 hours. 
When 300 mg of etoposide was administered intraperitoneally (Case 6)， transportation into 
the bloodstream increased. The maximum blood etoposide level observed was 2.5 times more 
than seen with the 100 mg dose， i. e. 10μg/ml. This level was maintained for about 4 hours. 
At twenty-four hours after i. p. administration of 300 mg of etoposide， 2μg/ml was sti1 found 
in the blood (Fig. 3). 
Analy自isusing the compartment model 
The pharmacokinetics of etoposide in ascites in the six cases， as determined by using the 
(306) T. Noda， etal. 
compartment model， are shown in Table 2. Analyses were based on the two-compartment 
model， but because the mode of disappearance of etoposide from the ascites was monophasic 
in Cases 1 and 2， a one-compartment model was applied to these cases 
Generally， intraperitoneally administered drugs show a two-phase elimination pattern Cα 
and βphases) but in this study there was considerable variation among the cases. The half-
life in the αphase was 1.4 hours on average， and in theβphase， 29 hours. 
When the peritoneum was intact and ascites was not found， as in Case 1， the etoposide level 
in the abdominal fluid as expressed by the area under the curve CAUC) was lower， 164μg. h./ 
ml， and the rate of disappearance from the abdominal cavity CKel) was rapid ; thus， the 
peritoneal clearance CClp) was higher. 
1n contrast， Cases 2， 3， 5 and 6 involved advanced cancerous peritonitis， and etoposide levels 
in the ascites as expressed by AUC were higher than 500μg. h./ml. The rate of disappearance 
from the abdominal cavity in these cases was low， and thus the peritoneal clearance CClp) was 
also low 
Moment analysis 
These indices were calculated ; the AUC was the zero-order moment， the mean residence 
time CMRT) was the primary moment， and the variance of residence time CVRT) was the 
second moment CTable 3). 
Tabl巴 2.Pharmacokinetic parameters of ascites in six patient receiving i. p. etoposide 
Patient AUC t1!2α tll2 Clp k12 k21 Kel V1 V2 Vs atlent (ug.h/ml) (h) (h) (ml/min) (h-l) (h-l) (h-l) (I) (I) (I) 
1キ 164 0.40 10.2 1. 75 0.35 
2 * 908 7.4 1.39 0.0934 1.18 
3叫 694 0.11 31.4 2.40 4.90 0.104 1.34 0.11 5.07 5.18 
4串申串
5叫 521 1.72 17 .2 3.20 0.l31 0.246 0.0659 2.91 1.55 4.46 
6村 4680 2.30 38.7 1目。7 0.0601 0.236 。.0228 1.18 0.30 1.49 
* on巴 compartm巴ntmodel * two . compartment model帥*sample not obtained 
Tabl巴 3目 Pharmacokineticparam巴t巴rsof i. p. etoposide in ascit巴sand plasma of six patients by moment 
analysis 
Patient AUC t 1/2 MRT VRT Clp AUC (ug h/ml) (h) (h) (h2) (ml/min) ratio 
Ascites 162 0.44 0.81 0.41 10目3 4.1 
Plasma 39.2 10.2 10.4 175 42.5 
Ascites 1150 8.2 12.5 126 1目45 27.1 
Plasma 42.4 7.6 11.5 117 39.3 
Ascites 1440 105 105 20300 1目 16 17.8 
Plasma 81.1 16.3 18.2 485 20.6 
Ascitesキ
Plasmaキ*
Ascites 534 17.3 23.2 616 3.12 
Plasma*市
Ascites 4880 34.9 50.0 2540 l.l4 26.3 
Plasma 185 8目4 12.5 147 27.0 
* sample not obtained 
川 analysisimpossible due to lack of illumination phase 
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The AUC of etoposide in the ascites of subjects with advanced cancerous peritonitis CCases 
2， 3， 5 and 6) was more than five-fold that of the subject with an intact peritoneum CCase 1)， 
the MRT was more than 15-fold greater， and the VRT more than 300-fold. 
AUC， MRT and VRT values for etoposide transported into the blood stream were slightly 
higher in the cases with cancerous peritonitis than in Case 1. The AUC ratio was 4.1 in Case 
1 and ranged from 17.8 to 27.1 in cases of cancrous peritonitis. 
Integrated urinary excretion 
The integrated urinbry excretion of etoposide after 100 mg intraperitoneal administration is 
shown in Fig. 4. Twenty-four hours after administration， 30 to 40% of the dose administered 
had been excreted in urine 
Clinical effect 
In the present study， after three cycles of EP therapy Cetoposide with cisplatinum)， responses 
were evaluated by the criteria of primary response to chemotherapy for ovarian cancer， 
authorized by the ]apan Society for Cancer Therapy. As for ascites， one case CCase 2) showed 
complete response CCR) ; two others CCases 4， 6) demonstrated partial response (PR)， and the 
rest CCase 5) remained no change (NC). However， PR with Case 2 and minor response (MR) 
with Case 3 were shown with respect to measurable lesions. 
Pharmacokinetics of intraperitoneal巴toposide
DISCUSSION 
In many cases， ovarian carcinoma tends to remain limited to the peritoneal cavity throughout 
most of its clinical course. Therefore， the most important factor in a successful therapeutic 
strategy for ovarian cancer is control of the disease during its intraperitoneal stage. One 

















Fig. 4目 Urinaryexcretion of etoposide after i. p.， i. v. and p. o. administration. 
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regard， intraperitoneal administration of cisplatinum (CDDP) has proved to be effective， and 
the pharmacokinetics of this drug have been well documented9，10，11，12). 
Etoposide is a semisynthetic glycoside of podophyllotoxin， an extract of the plant Podophyl同
lum， that is effective as a second-line drug for refractory ovarian cancer3，4). As for a phase 1 
I study of combination chemotherapy with intraperitoneal cisplatin (90 mg/mりandsystemic 
etoposide in advanced ovarian cance， the recommended dose of etoposide was reported to be 
600 mg/m2，13). In our clinical trial， the dose of etoposide was defined to be 100 mg/subject and 
escalated to 300 mg/subject in an individual case， considering the sufficient safety margin of 
intraperitoneally administered etoposide. It is usually administered orally or intravenously and 
there is litle information regarding its effects after intraperitoneal administration14，lS) 
In the present study， we administered etoposide intraperitoneally to patients with cancerous 
peritonitis， and investigated the pharmacokinetics of the drug. 
There were some individual variations， but generally the highest level of etoposide in the 
ascites 000μg/ml) was obtained immediately after 100 mg i. p. administration. The level was 
more than 1μg/ml until 48 hours after administration. 
Transportation in to the bloodstream via the intraperitoneal route was also good. The 
maximum serum level was 5μg/ml. Twenty-four hours after administration， the serum level 
of etoposide was stil 1μg/ml. 
In this study， only total etoposide levels were measured. Free etoposide (the active antican-
cer form) was not measured ; however， a high intraperitoneal concentration of etoposide after 
100 mg i.p. seems to be sufficient to kil free malignant cells directly in the abdominal cavity. 
The anticancer effect via the vascular system of the tumor after 100 mg i.p. administration， 
as shown in Fig. 3， must be comparable to the effects after intravenous or oral administration16). 
The considerable variation in ascites and serum concentration observed among the cases may 
be a result of the stage of cancerous peritonitis. When the peritoneum was intact and there was 
no ascites， the Kel of etoposide from the abdominal cavity was large and Clp was high， 
indicating good transportation of etoposide into the bloodstream. Consequently， the AUC of 
etoposide in peritoneal fluid.was low. 
In 
Pharmacokinetics of intraperitoneal etoposid巴 (309) 
The anticancer effect of etoposide is apparently limited ; thus， simultaneous administration 
of CDDP should yield a synergistic effect. In this study， we administered both CDDP and 
etoposide intraperitoneally. This combination yielded a partial response in resistant and 
recurrent cases. Thus， etoposide may be useful as a second-line drug for treating recurrent 
cancerous peritonitis. Nevertheless， the reason why no reponses were shows in pancreatic 
cancer CCase 5) seemed to depend upon its primary sensitivity to anticancer agents. At this 
time， there is no effective single agent or combination chemotherapy program for pancreatic 
cancer， and progress wi1 depend upon the development of newer agents. 
Etoposide is a cell--cyc1e phase-specific drug， and the magnitude of its effect therefore relies 
on the duration of exposure above a certain concentration則的. In small-cell1ungcancer， the 
c1inical effect of etoposide is largely dependent on long-duration exposure to more than 1μg/ 
ml of the drug. An administration schedule that accounts for this fact is therefore 
necessary20，21). Thus， the most effective schedule for intraperitoneal administration of 
etoposide may be 100 mg/day i. p. for five days， rather than a one-shot bolus intraperitoneal 
administration. 
We are now investigating the effect of continuous intraperitoneal administration of etoposide 
for five days. More c1inical experience is required to establish the efficacy of intraperitoneal 
administratiοn of etoposide. 
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